Exhibit 99.1 Kura Oncology Reports Second Quarter 2025 Financial Results – FDA Priority Review of New Drug Application (NDA) for ziftomenib in adults with R/R NPM1-m AML with Prescription Drug User Fee Act (PDUFA) target action date set for November 30, 2025 – – Fully engaged in commercial readiness activities in alignment with regulatory review timeline – – $630.7 million in pro forma cash, together with anticipated collaboration agreement payments, expected to support ziftomenib commercialization through ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC. 20549 FORM 10-Q (Mark One) For the transition period from __________ to __________ Commission File Number: 000-50175 DORCHESTER MINERALS, L.P. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) Delaware 81-0551518 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly per ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission file number 001-41849 Mach Natural Resources LP (Exact name of registrant as specified in its charter) Delaware 9 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-38485 Amneal Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Washington, D.C. 20549 Form 10-Q (State or other jurisdiction of incorporation or o ...

Exhibit 99.1 We have not reconciled forward-looking Adjusted EBITDA to net income (loss), the most directly comparable GAAP measure, because we cannot predict with reasonable certainty the ultimate outcome of certain components of 1 • GMV was $504 million, an increase of 14% compared to the same period in 2024 • Total Revenue was $165 million, an increase of 14% compared to the same period in 2024 • Gross Profit was $123 million, an increase of $15 million compared to the same period in 2024 • Gross Margin ...

KINGSWAY REPORTS Second QUARTER 2025 FINANCIAL RESULTS Management to Host Conference Call Today, August 7, 2025, at 5 p.m. ET Chicago - August 7, 2025 - (NYSE: KFS) Kingsway Financial Services Inc. ("Kingsway" or the "Company"), the only publicly-traded US company employing the Search Fund model to acquire and build great businesses, today announced its operating results for the three and six months ended June 30, 2025. Second Quarter 2025 Consolidated Financial Highlights Recent Business Highlights ● Conso ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended June 30, 2025 OR Texas 76-0509661 5301 Hollister, Houston, Texas 77040 (Address of principal executive offices, including zip code) ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from __________ to __________ Commission file n ...

* instacart Q2 2025 Letter to Shareholders August 7, 2025 instacart Dear Shareholders, We delivered another strong quarter, reinforcing the essential role we play in helping families save time, money, and effort putting food on the table. In Q2, we grew orders by 17% year-over-year to 82.7 million and increased GTV by 11% year-over-year to $9,081 million. We also delivered net income of $116 million and Adjusted EBITDA of $262 million. Our strategy is working: we're accelerating online grocery adoption by c ...

Exhibit 99.1 10x Genomics Reports Second Quarter 2025 Financial Results PLEASANTON, Calif. August 7, 2025 – 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the second quarter ended June 30, 2025. Recent Updates "The second quarter unfolded largely as anticipated," said Serge Saxonov, Co-founder and CEO of 10x Genomics. "Amid continued uncertainty in the funding environment, we're encouraged by the resilience of our business and the dedicati ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 PureCycle Technologies, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation) Delaware 001-40234 86-2293091 (Commission File Number) (IRS Employer Identification No.) 20 North Orange Avenue, Suite 106 Orlando, Florida 32801 (Ad ...